SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma

Suzanne Lentzsch, Gary Elliott, G. David Roodman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Non-steroidal anti-inflammatory drugs have been shown to inhibit carcinogenesis in colon cancer, and to induce apoptosis in a variety of tumor cell lines. Some anti-tumor effects are thought to be related to their cyclooxygenase-2-inhibitory activity, but recent studies have shown that non-steroidal anti-inflammatory drugs exert their anti-tumor effect via cyclooxygenase-2-independent mechanism. SDX-308 (CEP-18082) is a non-cyclooxygenase-2-inhibiting indole-pyran analog and is structurally related to SDX-101, an R-enantiomer of etodolac. SDX-308 has a potent anti-myeloma effect and shows synergism in combination with other drugs for the treatment of chronic lymphocytic leukemia. In addition SDX-308 inhibits osteoclast formation and activity and thereby might be an attractive drug for the treatment of diseases with increased osteoclast activity such as osteolytic lesions in multiple myeloma and metastatic carcinomas, as well as osteoporosis. This review covers future application of SDX-308 as an anti-myeloma drug regulating increased osteoclast activity.

Original languageEnglish (US)
Pages (from-to)511-516
Number of pages6
JournalArchiv der Pharmazie
Volume340
Issue number10
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Hematologic Neoplasms
Anti-Inflammatory Agents
Osteoclasts
Tumors
Pharmaceutical Preparations
Cyclooxygenase 2
Etodolac
Pyrans
Therapeutics
Enantiomers
B-Cell Chronic Lymphocytic Leukemia
Tumor Cell Line
Multiple Myeloma
Colonic Neoplasms
Osteoporosis
Neoplasms
Carcinogenesis
Cells
SDX 308
Apoptosis

Keywords

  • Anticancer activity
  • CEP-18082
  • Multiple myeloma
  • SDX-308

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Pharmacology

Cite this

SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma. / Lentzsch, Suzanne; Elliott, Gary; Roodman, G. David.

In: Archiv der Pharmazie, Vol. 340, No. 10, 10.2007, p. 511-516.

Research output: Contribution to journalArticle

@article{5edae5ae688b4c8298b66eae17e46547,
title = "SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma",
abstract = "Non-steroidal anti-inflammatory drugs have been shown to inhibit carcinogenesis in colon cancer, and to induce apoptosis in a variety of tumor cell lines. Some anti-tumor effects are thought to be related to their cyclooxygenase-2-inhibitory activity, but recent studies have shown that non-steroidal anti-inflammatory drugs exert their anti-tumor effect via cyclooxygenase-2-independent mechanism. SDX-308 (CEP-18082) is a non-cyclooxygenase-2-inhibiting indole-pyran analog and is structurally related to SDX-101, an R-enantiomer of etodolac. SDX-308 has a potent anti-myeloma effect and shows synergism in combination with other drugs for the treatment of chronic lymphocytic leukemia. In addition SDX-308 inhibits osteoclast formation and activity and thereby might be an attractive drug for the treatment of diseases with increased osteoclast activity such as osteolytic lesions in multiple myeloma and metastatic carcinomas, as well as osteoporosis. This review covers future application of SDX-308 as an anti-myeloma drug regulating increased osteoclast activity.",
keywords = "Anticancer activity, CEP-18082, Multiple myeloma, SDX-308",
author = "Suzanne Lentzsch and Gary Elliott and Roodman, {G. David}",
year = "2007",
month = "10",
doi = "10.1002/ardp.200700081",
language = "English (US)",
volume = "340",
pages = "511--516",
journal = "Archiv der Pharmazie",
issn = "0365-6233",
publisher = "Wiley-VCH Verlag",
number = "10",

}

TY - JOUR

T1 - SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma

AU - Lentzsch, Suzanne

AU - Elliott, Gary

AU - Roodman, G. David

PY - 2007/10

Y1 - 2007/10

N2 - Non-steroidal anti-inflammatory drugs have been shown to inhibit carcinogenesis in colon cancer, and to induce apoptosis in a variety of tumor cell lines. Some anti-tumor effects are thought to be related to their cyclooxygenase-2-inhibitory activity, but recent studies have shown that non-steroidal anti-inflammatory drugs exert their anti-tumor effect via cyclooxygenase-2-independent mechanism. SDX-308 (CEP-18082) is a non-cyclooxygenase-2-inhibiting indole-pyran analog and is structurally related to SDX-101, an R-enantiomer of etodolac. SDX-308 has a potent anti-myeloma effect and shows synergism in combination with other drugs for the treatment of chronic lymphocytic leukemia. In addition SDX-308 inhibits osteoclast formation and activity and thereby might be an attractive drug for the treatment of diseases with increased osteoclast activity such as osteolytic lesions in multiple myeloma and metastatic carcinomas, as well as osteoporosis. This review covers future application of SDX-308 as an anti-myeloma drug regulating increased osteoclast activity.

AB - Non-steroidal anti-inflammatory drugs have been shown to inhibit carcinogenesis in colon cancer, and to induce apoptosis in a variety of tumor cell lines. Some anti-tumor effects are thought to be related to their cyclooxygenase-2-inhibitory activity, but recent studies have shown that non-steroidal anti-inflammatory drugs exert their anti-tumor effect via cyclooxygenase-2-independent mechanism. SDX-308 (CEP-18082) is a non-cyclooxygenase-2-inhibiting indole-pyran analog and is structurally related to SDX-101, an R-enantiomer of etodolac. SDX-308 has a potent anti-myeloma effect and shows synergism in combination with other drugs for the treatment of chronic lymphocytic leukemia. In addition SDX-308 inhibits osteoclast formation and activity and thereby might be an attractive drug for the treatment of diseases with increased osteoclast activity such as osteolytic lesions in multiple myeloma and metastatic carcinomas, as well as osteoporosis. This review covers future application of SDX-308 as an anti-myeloma drug regulating increased osteoclast activity.

KW - Anticancer activity

KW - CEP-18082

KW - Multiple myeloma

KW - SDX-308

UR - http://www.scopus.com/inward/record.url?scp=35548984453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35548984453&partnerID=8YFLogxK

U2 - 10.1002/ardp.200700081

DO - 10.1002/ardp.200700081

M3 - Article

C2 - 17849446

AN - SCOPUS:35548984453

VL - 340

SP - 511

EP - 516

JO - Archiv der Pharmazie

JF - Archiv der Pharmazie

SN - 0365-6233

IS - 10

ER -